Updated:
TVM Capital Life Science
TVM Capital Life Science is an international venture capital firm focused on life sciences. It provides capital and expertise to develop and market products...
TVM Capital Life Science
TVM Capital Life Science is an international venture capital firm focused on life sciences. It provides capital and expertise to develop and market products with the potential to transform medical practice while building value for investors. The firm uses a dual-investment approach: financing innovative early-stage therapeutics through single-asset companies in strategic relationship with Eli Lilly and Company, and investing in commercial-stage medtech, diagnostics, digital health, and late-stage therapeutics.
General information
Firm type
Private Equity
Year founded
1983
Location
Region
Europe
Country
Germany
City
Montreal, Quebec
Corporate office
Munich, Germany
Principals
Hubert Birner
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at TVM Capital Life Science?
Managing Partner Hubert Birner is the central investment authority, having led the firm's life science franchise since its early days. Investment committees operate within each fund strategy — biotech venture and healthcare services buy-and-build — drawing on partner-level expertise for asset selection. Day-to-day deal execution involves a transatlantic team of sector specialists.
How is TVM Capital Life Science related to the broader TVM Capital platform?
TVM Capital Life Science represents the life science-focused arm of the TVM Capital group, which historically maintained separate vehicles for technology and growth equity in other sectors. The life science team operates with distinct fund mandates and a dedicated Munich-based partnership under Hubert Birner. Cross-pollination across strategies is limited given the specialized nature of healthcare investing.
What geographies does TVM Capital Life Science cover?
Core activity centers on German-speaking Europe (DACH region), with selective mandates extending to broader Continental Europe and North America. The firm evaluates Canadian biotech assets in certain fund vintages, though disclosed portfolio density is highest in Germany and Switzerland.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: